These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37021137)

  • 1. Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study.
    Berton AM; Parasiliti-Caprino M; Prencipe N; Bioletto F; Lopez C; Bona C; Caputo M; Rumbolo F; Ponzetto F; Settanni F; Gasco V; Mengozzi G; Ghigo E; Grottoli S; Maccario M; Benso AS
    Front Neurosci; 2023; 17():1098404. PubMed ID: 37021137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter 2 Inhibitor Combined with Conventional Diuretics Ameliorate Body Fluid Retention without Excessive Plasma Volume Reduction.
    Asakura-Kinoshita M; Masuda T; Oka K; Ohara K; Miura M; Morinari M; Misawa K; Miyazawa Y; Akimoto T; Shimada K; Nagata D
    Diagnostics (Basel); 2024 Jun; 14(11):. PubMed ID: 38893720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.
    Lytvyn Y; Bjornstad P; Katz A; Singh SK; Godoy LC; Chung LT; Vinovskis CL; Pyle L; Roussel R; Perkins BA; Cherney D
    Diabetes Metab; 2020 Jun; 46(3):203-209. PubMed ID: 31816431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis.
    Christ-Crain M; Fenske W
    Nat Rev Endocrinol; 2016 Mar; 12(3):168-76. PubMed ID: 26794439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy Volunteers.
    Fenske WK; Schnyder I; Koch G; Walti C; Pfister M; Kopp P; Fassnacht M; Strauss K; Christ-Crain M
    J Clin Endocrinol Metab; 2018 Feb; 103(2):505-513. PubMed ID: 29267966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.
    Scholtes RA; Muskiet MHA; van Baar MJB; Hesp AC; Greasley PJ; Hammarstedt A; Karlsson C; Hallow KM; Danser AHJ; Heerspink HJL; van Raalte DH
    Kidney Int Rep; 2022 May; 7(5):1084-1092. PubMed ID: 35570989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopressin and Copeptin in health and disease.
    Christ-Crain M
    Rev Endocr Metab Disord; 2019 Sep; 20(3):283-294. PubMed ID: 31656992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial.
    Oka K; Masuda T; Ohara K; Miura M; Morinari M; Misawa K; Miyazawa Y; Akimoto T; Shimada K; Nagata D
    Front Med (Lausanne); 2023; 10():1287066. PubMed ID: 38155663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.
    Szinnai G; Morgenthaler NG; Berneis K; Struck J; Müller B; Keller U; Christ-Crain M
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3973-8. PubMed ID: 17635944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osmotic stimulation of vasopressin acutely impairs glucose regulation: a counterbalanced, crossover trial.
    Jansen LT; Suh H; Adams JD; Sprong CA; Seal AD; Scott DM; Butts CL; Melander O; Kirkland TW; Vanhaecke T; Dolci A; Lemetais G; Perrier ET; Kavouras SA
    Am J Clin Nutr; 2019 Dec; 110(6):1344-1352. PubMed ID: 31562496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
    Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
    Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copeptin Kinetics and Its Relationship to Osmolality During Rehydration for Diabetic Ketoacidosis in Children.
    Burckhardt MA; Gotta V; Beglinger S; Renggli L; Bachmann S; Hess M; Rentsch K; Pfister M; Koch G; Davis EA; Zumsteg U; Jones TW; Szinnai G
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32835363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).
    Boertien WE; Riphagen IJ; Drion I; Alkhalaf A; Bakker SJ; Groenier KH; Struck J; de Jong PE; Bilo HJ; Kleefstra N; Gansevoort RT
    Diabetologia; 2013 Aug; 56(8):1680-8. PubMed ID: 23624546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arginine vasopressin, fluid balance and exercise: is exercise-associated hyponatraemia a disorder of arginine vasopressin secretion?
    Hew-Butler T
    Sports Med; 2010 Jun; 40(6):459-79. PubMed ID: 20524712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects.
    Zanchi A; Pruijm M; Muller ME; Ghajarzadeh-Wurzner A; Maillard M; Dufour N; Bonny O; Wuerzner G; Burnier M
    Front Cardiovasc Med; 2022; 9():854230. PubMed ID: 35391843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copeptin in fluid disorders and stress.
    Mu D; Ma C; Cheng J; Zou Y; Qiu L; Cheng X
    Clin Chim Acta; 2022 Apr; 529():46-60. PubMed ID: 35143773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus.
    Nakagaito M; Joho S; Ushijima R; Nakamura M; Kinugawa K
    Circ Rep; 2019 Sep; 1(10):405-413. PubMed ID: 33693077
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease.
    Golembiewska E; Machowska A; Stenvinkel P; Lindholm B
    Curr Protein Pept Sci; 2017; 18(12):1232-1243. PubMed ID: 28714397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.